Growth Hormone Secretagogue Mechanisms: GHRH vs Ghrelin Pathways
CJC-1295 no DAC functions as a modified GHRH (growth hormone-releasing hormone) analog. It binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering cAMP-mediated calcium influx and subsequent GH vesicle exocytosis. The 'no DAC' design
This comparison does not assign a generated winner or score.
- CJC-1295 no DAC functions as a modified GHRH (growth hormone-releasing hormone) analog. It binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering cAMP-mediated calcium influx and subsequent GH vesicle exocytosis. The 'no DAC' designation means it lacks the Drug Affinity Complex modification that extends half-life to multiple days; without DAC, the peptide maintains a plasma half-life of approximately 30 minutes to 2 hours, producing a discrete GH pulse rather than sustained elevation.
- Ghrelin receptor agonists (the GHS class) work through an entirely separate pathway. These peptides. Ipamorelin, Hexarelin, GHRP-2, and GHRP-6. Bind to the ghrelin receptor (GHS-R1a), which exists both in the pituitary and the hypothalamus. Activation triggers GH release through two mechanisms simultaneously: direct pituitary secretion (like GHRH) and hypothalamic suppression of somatostatin, the hormone that inhibits GH release between pulses. This dual action is why ghrelin mimetics often produce larger GH pulses than GHRH analogs at equivalent molar doses. They're not just stepping on the gas, they're also removing the brake.
- The practical research implication: GHRH analogs like CJC-1295 no DAC produce clean, predictable GH pulses with minimal off-target effects. Ghrelin agonists produce larger pulses but come with secondary signaling. Appetite modulation (ghrelin is the 'hunger hormone'), potential cortisol co-release (depending on the specific analog), and in some cases, cardioprotective or neuroprotective effects unrelated to GH itself. Neither approach is 'better'. They're suited to different experimental questions.